Vivek Subbiah: Our commentary on Precision oncology across the ages

Vivek Subbiah shared on LinkedIn about a recent paper titled “Precision oncology across the ages: Impact on children, adolescents, and young adults” published in Cancer Cell.

Authors: Vivek Subbiah, Razelle Kurzrock

“Hot off the press. Pleased to share with the our commentary published in Cancer Cell Cell Press!

Precision oncology across the ages: Impact on children, adolescents, and young adults.

Yes! Precision Oncology Is Age and Tissue-Agnostic.

Precision oncology endeavors to tailor therapies based on individual patient and tumor characteristics. This rapidly evolving field has transformed cancer treatment across all age groups. In this commentary, we review the application of precision oncology across different age groups, specifically in children, adolescents, and young adults, and emphasize that precision medicine is age and tissue agnostic.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials.

His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.